Impact of type 2 diabetes on the plasma levels of vascular endothelial growth factor and its soluble receptors type 1 and type 2 in patients with peripheral arterial disease

• Published in: Journal of Zhejiang University. B. Science Vol. 16; no. 11; pp. 948 - 956
• Main Authors: Wieczór, Radosław, Gadomska, Grażyna, Ruszkowska-Ciastek, Barbara, Stankowska, Katarzyna, Budzyński, Jacek, Fabisiak, Jacek, Suppan, Karol, Pulkowski, Grzegorz, Rość, Danuta
• Format: Journal Article
• Language: English
• Published: Hangzhou Zhejiang University Press 01.11.2015; Springer Nature B.V
• Subjects: Aged; Angiogenesis; Angiogenesis inhibitors; Assaying; Biomedical and Life Sciences; Biomedicine; Blood vessels; Coexistence; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2 - blood; Diabetic Angiopathies - blood; Enzyme-linked immunosorbent assay; Family medical history; Female; Forming; Healing; Humans; Hyperglycemia; Hypoxia; Inhibitors; Ischemia; Limbs; Male; Middle Aged; Patients; Peripheral Arterial Disease - blood; Pharmacology; Plasma levels; Receptors; Subgroups; Therapy; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - blood; Vascular Endothelial Growth Factor Receptor-1 - blood; Vascular Endothelial Growth Factor Receptor-2 - blood; Angiogenesis; 可溶性受体; 外周动脉疾病; R587.1; Peripheral arterial disease; Soluble receptors; Type 2 diabetes mellitus; 血管生成; Vascular endothelial growth factor; 血管内皮生长因子; 2 型糖尿病
• ISSN: 1673-1581; 1862-1783
• DOI: 10.1631/jzus.B1500076

Objective Type 2 diabetes coexistent with lower extremity artery disease (peripheral arterial disease (PAD)) can be observed in numerous patients. The mechanism compensating for ischemia and contributing to healing is angiogenesis—the process of forming new blood vessels. The purpose of this study was to assess the likely impact of type 2 diabetes on the plasma levels of proangiogenic factor (vascular endothelial growth factor A (VEGF-A)) and angiogenesis inhibitors (soluble VEGF receptors type 1 and type 2 (sVEGFR-1 and sVEGFR-2)) in patients with PAD. Method Among 46 patients with PAD under pharmacological therapy (non-invasive), we identified, based on medical history, a subgroup with coexistent type 2 diabetes (PAD-DM2+, n =15) and without diabetes (PAD-DM2−, n =31). The control group consisted of 30 healthy subjects. Plasma levels of VEGF-A, sVEGFR-1, and sVEGFR-2 were measured using the enzyme-linked immunosorbent assay (ELISA) method. Results The subgroups of PAD-DM2+ and PAD-DM2−revealed significantly higher concentrations of VEGF-A ( P =0.000 007 and P =0.000 000 1, respectively) and significantly lower sVEGFR-2 levels ( P =0.02 and P =0.000 01, respectively), when compared with the control group. Patients with PAD and coexistent diabetes tended to have a lower level of VEGF-A and higher levels of sVEGFR-1 and sVEGFR-2 comparable with non-diabetic patients. Conclusions The coexistence of type 2 diabetes and PAD is demonstrated by a tendency to a lower plasma level of proangiogenic factor (VEGF-A) and higher levels of angiogenesis inhibitors (sVEGFR-1 and sVEGFR-2) at the same time. Regardless of the coexistence of type 2 diabetes, hypoxia appears to be a crucial factor stimulating the processes of angiogenesis in PAD patients comparable with healthy individuals, whereas hyperglycemia may have a negative impact on angiogenesis in lower limbs.